文献速递儿童心血管与肾脏

儿童慢性肾脏病降压药比较效果:RAASi优于CCB

Comparative Effectiveness of Antihypertensive Medications in Children With Chronic Kidney Disease.
PubMed 文献 · JAMA Pediatr · 2026-01-01

本研究采用目标试验模拟方法,基于PRESERVE研究2009至2020年13家机构电子健康记录,纳入2762例2至20.9岁CKD 2-4期高血压患儿,比较初始RAASi与CCB治疗对肾功能保护的效果。调整分析显示RAASi与肾脏替代治疗风险降低相关(aHR 0.58),且收缩压控制优于CCB。

要点

  • 儿童CKD高血压初始RAASi治疗与2年内肾脏替代治疗风险降低相关(aHR 0.58)。
  • RAASi组收缩压高于90百分位的时间比例低于CCB组(29% vs 39%)。
  • 结果支持RAASi作为儿童CKD降压治疗的一线选择。

核心结论

  • 在儿童CKD 2-4期高血压患者中,初始RAASi治疗与CCB相比,肾脏替代治疗风险更低且血压控制更好。

研究设计与样本

  • 采用目标试验模拟方法,利用PRESERVE研究2009年1月至2020年12月电子健康记录,覆盖5个PCORnet临床研究网络13家机构。
  • 纳入2至20.9岁CKD 2-4期且收缩压高于90百分位或诊断高血压并初始RAASi或CCB治疗的儿童青少年,共2762例。
  • 通过倾向评分加权模拟随机化,平衡社会人口学、机构、年份、CKD病因、蛋白尿、CKD分期、肥胖、医疗使用、药物、合并症及血压控制等因素。

主要发现

  • 1757例初始RAASi(中位年龄13.1岁,男性51.1%),1005例初始CCB(中位年龄12.6岁,男性49.8%)。
  • RAASi与复合终点(肾脏替代治疗、eGFR下降50%或eGFR<15 mL/min/1.73 m2)风险降低相关(aHR 0.67;95%CI 0.53-0.83)。
  • RAASi组收缩压高于90百分位的时间比例为29%,CCB组为39%。

关键数值与推荐

  • 主要结局为2年内进展至肾脏替代治疗,通过链接美国肾脏数据系统确认。
  • 次要结局为肾脏替代治疗、eGFR下降50%或eGFR<15 mL/min/1.73 m2的复合终点。
  • 采用Cox比例风险回归与倾向评分分层估计调整风险比,意向性治疗分析。

临床怎么用

  • 儿童CKD 2-4期合并高血压时,可优先考虑RAASi作为初始降压治疗以延缓肾功能进展。
  • 选择RAASi可能有助于改善收缩压控制,但需结合患儿个体情况评估。

局限性

  • 本研究为目标试验模拟的观察性研究,非随机对照试验,可能存在未测量混杂。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Hypertension is a major modifiable factor for kidney function decline in chronic kidney disease (CKD). Comparative trials of antihypertensive medications in pediatric CKD are lacking. OBJECTIVE: To evaluate the comparative effectiveness of renin-angiotensin-aldosterone system inhibition (RAASi) vs calcium channel blockade (CCB), the most widely used first-line antihypertensive treatment approaches in pediatric CKD, on preservation of kidney function. DESIGN, SETTING, AND PARTICIPANTS: Using target trial emulation methods, this comparative-effectiveness study emulated a pragmatic, open-label clinical trial using electronic health record data from the Preserving Kidney Function in Children with CKD (PRESERVE) study from January 2009 through December 2020. Thirteen health care institutions from 5 PCORnet Clinical Research Networks were represented. Children and adolescents aged 2 to 20.9 years with CKD stage 2-4 and systolic blood pressure higher than the 90th percentile or with a hypertension diagnosis who initiated treatment with RAASi or CCB were included. Exclusion criteria included kidney replacement therapy, renal artery stenosis, malignancy, and pregnancy. Data analysis was completed in July 2025. EXPOSURES: Incident RAASi or CCB treatment. Randomization was emulated by propensity score weighting to balance groups on sociodemographic factors, institution, year, CKD etiology, proteinuria, CKD stage, obesity, health care use, medications, comorbidities, and blood pressure control (percentage of time at greater than the 90th percentile). MAIN OUTCOMES AND MEASURES: The primary outcome was progression to kidney replacement therapy within 2 years of follow-up, ascertained through linkage with the United States Renal Data System. The secondary outcome was a composite of kidney replacement therapy, 50% decline in estimated glomerular filtration rate, or estimated glomerular filtration rate less than 15 mL/min/1.73 m2. Cox proportional hazards regression with propensity score stratification was used to estimate adjusted hazard ratios (aHRs) in the intention-to-treat analysis. Adjusted analyses also compared systolic blood pressure control within 2 years of follow-up. RESULTS: Of 2762 children and adolescents, 1757 initiated RAASi (median [IQR] age, 13.1 [9.2-15.5] years; 897 [51.1%] male) and 1005 initiated CCB (median [IQR] age, 12.6 [8.4-15.3] years; 500 [49.8%] male). In adjusted analyses, RAASi was associated with reduced risk of both kidney replacement therapy (aHR, 0.58; 95% CI, 0.40-0.84, P = .004) and the secondary composite outcome (aHR, 0.67; 95% CI, 0.53-0.83). Systolic blood pressure control was better with RAASi than CCB (29% vs 39% of time >90th percentile). CONCLUSIONS AND RELEVANCE: In this comparative-effectiveness study, RAASi was associated with lower risk of CKD progression and better blood pressure control compared to CCB. Findings support first-line use of RAASi for antihypertensive treatment in pediatric CKD.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Denburg MR, Goodwin Davies AJ, Maltenfort MG, et al. Comparative Effectiveness of Antihypertensive Medications in Children With Chronic Kidney Disease. JAMA Pediatr. 2026. PMID: 41837993. doi:10.1001/jamapediatrics.2026.0207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。